John Sterling is the Editor in Chief of Genetic Engineering & Biotechnology News. With a focus on biotechnology and precision medicine, John's articles provide insights into the latest advancements and challenges in the field. His work has also been featured in publications such as Inside Precision Medicine and Upstate Business Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
John Sterling's articles primarily focus on scientific and healthcare & pharmaceutical topics, with a specific emphasis on biopharmaceutical manufacturing, bioprocessing, cell therapy, drug discovery, and biotechnology. His coverage attributes show a strong reliance on press releases and data citations.
To effectively reach out to John Sterling for potential coverage or commentary opportunities related to the mentioned themes and topics, consider offering detailed insights supported by credible data from reputable sources within the relevant industries. Additionally, providing access to newsworthy announcements or industry-specific developments may enhance the appeal of your pitch when approaching him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Sterling
“New treatment combinations could one day be developed that take this new role for RAS into consideration,” said Lowy.
By: John Sterling
Lonza offers customers a fully integrated solution, spanning design and lead molecule generation, including Synaffix conjugation technology.
By: John Sterling
“This work opens up many new possibilities,” Long said. “For example, it might be possible for people in the future to consume BHB-Phe to drive weight loss without restricting carbohydrates in their diet.”
Credit: Cytiva SyVento Biotech, a CDMO, opened its new mRNA manufacturing facility, a FlexFactory delivered by Cytiva, spanning over 7,000
By: John Sterling
“The Biofoundry-in-a-Box is…the key component of Centillion's RNA-by-Design™ offering, for the delivery of regulatory ready, patient centric, and equitable access to advanced therapies,” said Harris Makatsoris, PhD, CEO at Centillion Technology. “The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical products, aligning with the rapid response needs of manufacturing accelerators as Quotient Sciences.”
By: John Sterling
Research teams are developing air pollution models to measure PM2.5 components in the Atlanta area.
By: John Sterling
Credit: Nitat Termmee/Getty Images Abzena, a CDMO, said it has expanded its early and late-phase analytical capabilities to now include GMP
By: John Sterling
RevOpsis says it is committed to the rapid discovery and development of novel multispecific therapies utilizing its modular RevMod™ Platform.
By: John Sterling
By understanding more about this cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD and possibly apply this knowledge to other tissues and conditions.
By: John Sterling
The new facility complements existing mammalian-derived product manufacturing at 6,000L and 20,000L scales provided from Portsmouth.
(833) 317-6278 
